Core Insights - NeuroBo Pharmaceuticals has completed the last patient visit in its two-part Phase 2a clinical trial for DA-1241, a GPR119 agonist targeting metabolic dysfunction-associated steatohepatitis (MASH), with topline data expected in December 2024 [1][2] Company Overview - NeuroBo Pharmaceuticals is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, currently developing DA-1241 for MASH and DA-1726 for obesity [6] Clinical Trial Details - The Phase 2a trial consists of two parts: Part 1 compares DA-1241 to placebo, while Part 2 evaluates DA-1241 in combination with sitagliptin [2] - A total of 109 patients were randomized, with 95 completing the dosing; the trial is designed as a 16-week, multicenter, randomized, double-blind, placebo-controlled study [2][3] Efficacy and Safety Evaluation - The primary endpoint for both parts of the trial is the change in alanine transaminase (ALT) levels at Week 16, with secondary endpoints including cholesterol levels and triglycerides [3] - Safety will be assessed through monitoring adverse events and laboratory abnormalities [3] Mechanism of Action - DA-1241 acts as a GPR119 agonist, promoting the release of gut peptides that influence glucose and lipid metabolism, with preclinical studies showing its potential in reducing liver inflammation and improving glucose control [5][6]
NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH